Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.

Bob T. Li,Tianhong Li,Melissa Lynne Johnson,Saiama N. Waqar,Viola W. Zhu,Sai-Hong Ignatius Ou,Jessica J. Lin,Ding Wang,Geoffrey I. Shapiro,Judy Sing-Zan Wang,Dazhi Liu,Yuqing Ye,Hana Kosar,Angela Hee,Greg Berk,Sean Zhang,Junsheng Wang,Manish R. Patel

Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.

2020

Bob T. Li
Tianhong Li
Melissa Lynne Johnson
Saiama N. Waqar
Viola W. Zhu
Sai-Hong Ignatius Ou
Jessica J. Lin
Ding Wang
Geoffrey I. Shapiro
Judy Sing-Zan Wang
Dazhi Liu
Yuqing Ye
Hana Kosar
Angela Hee
Greg Berk
Sean Zhang
Junsheng Wang
Manish R. Patel

3510Background: Pyrotinib is a potent, irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the erythroblastic leukemia viral oncogene homolog (erbB) receptors, whic...

Keywords:

Oncology
in patient
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations